- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05749484
Prediction of the Chronicization of Radiation-induced Acute Intestinal Injury (CRAII)
Prediction of the Chronicization of Radiation-induced Acute Intestinal Injury Based on the Expression Level of Immune Factors: a Prospective, Observational and Confirmatory Clinical Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study design and setting The study is a prospective, observational, confirmatory, single-center study in predicting the chronicization of radiation-induced acute intestinal injury based on the expression level of immune factors.
Participants Patients diagnosed with locally advanced rectal cancer, who undergo NCRT and TME at The Sixth Affiliated Hospital, Sun Yat-sen University and develop RAII during NCRT or within 1 month will be assessed for suitability for inclusion.
Inclusion criteria Written informed consent. 18-75 years of age. ECOG score for performance status is 0-2. Locally advanced rectal adenocarcinoma (T3-4/N+M0) with pathological and MRI diagnosis. Patient will undergo NCRT and TME therapies and develop RAII during NCRT or within 1 month.
Exclusion criteria Patients with other active malignant tumors. Patients who have received pelvic radiotherapy or immunotherapy. Pathological tissue cannot be obtained after TME. Patients with toxicity (CTCAE Grade ≥ 2) caused by previous treatment that has not subsided. Pregnant or lactating women.
Interventions The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
Outcomes The primary outcome is the AUC of chronicization of RAII predicted by the prediction model. The secondary outcomes are accuracy, precision, specificity, and sensitivity of this prediction model in predicting chronicization of RAII.
Recruitment Patients aged 18-75 years who have been diagnosed with locally advanced rectal cancer and consider NCRT+TME therapies and develop RAII during NCRT or within 1 month are eligible for the study. The study physicians will inform the patients about the study in detail. After obtaining informed consent, the patient is recruited to the study. We will follow up the occurrence and progression of radiation-induced intestinal injury within 1 year after TME. Expression levels of immune factors will be detected in pathological tissue after TME and applied to the prediction model to predict the chronicization of RAII.
Participant timeline Recruitment started in March 1, 2023 at The Sixth Affiliated Hospital, Sun Yat-sen University.
Sample size We plan to enroll 200 patients diagnosed with locally advanced rectal cancer by pathology and MRI, who undergo NCRT and TME and develop RAII during NCRT or within 1 month.
Data management, collection and monitoring All protocol-required information collected during the study will be entered by the investigator in the electronic case report forms (CRF). The investigator should complete the CRF as soon as possible after information is collected. An explanation should be given for all missing data. The completed CRF will be reviewed and signed by the investigator. The main investigator will continuously monitor data. Data will be stored in the secured network of Sun Yat-sen University and for security reasons, in an external hard drive which will be used to back up regularly the database.
Statistical methods For statistical analysis of the quantitative variables with normal distribution, the mean, standard deviation (SD), median and interquartile range will be calculated. Group comparisons will be made using t tests or Mann-Whitney U test for continuous variables. Associations between the categorical variables will be tested with the Chi-Square-test or the Fisher exact test, when appropriate. Paired values (before and after therapies) will be compared for each patient using a paired t test or a Wilcoxon test. The data will be analyzed using IBM SPSS Statistics for Windows, version 27.0 (IBM Corporation, Armonk, NY, USA). A significance threshold of p < 0.05 will be adopted for all tests.
Research ethic approval The study adheres to the Declaration of Helsinki on medical research protocols and ethics. The protocol was reviewed and approved by the Human Medical Ethics Committee of the Sixth Affiliated Hospital of Sun Yat-sen University (2023ZSLYEC-075).
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Yun-Long Wang, Ph.D
- Phone Number: +862085655907
- Email: wangylong7@mail.sysu.edu.cn
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Written informed consent. 18-75 years of age. ECOG score for performance status is 0-2. Locally advanced rectal adenocarcinoma (T3-4/N+M0) with pathological and MRI diagnosis. Patient will undergo NCRT and TME therapies and develop RAII during NCRT or within 1 month.
Exclusion Criteria:
- Patients with other active malignant tumors. Patients who have received pelvic radiotherapy or immunotherapy. Pathological tissue cannot be obtained after TME. Patients with toxicity (CTCAE Grade ≥ 2) caused by previous treatment that has not subsided. Pregnant or lactating women.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
NCRT+TME
Neoadjuvant chemoradiotherapy (NCRT) and total mesorectal excision (TME) Interventions
|
The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC
Time Frame: 1 year after TME
|
Area Under Curve of the prediction model in predicting chronicization of RAII.
|
1 year after TME
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Accuracy, precision, specificity, and sensitivity
Time Frame: 1 year after TME
|
Accuracy, precision, specificity, and sensitivity of the prediction model in predicting chronicization of RAII.
|
1 year after TME
|
Collaborators and Investigators
Investigators
- Principal Investigator: Yun-Long Wang, Ph.D, The Sixth Affiliated Hospital, Sun Yat-sen University
Publications and helpful links
General Publications
- Fan J, Lin B, Fan M, Niu T, Gao F, Tan B, Du X. Research progress on the mechanism of radiation enteritis. Front Oncol. 2022 Sep 5;12:888962. doi: 10.3389/fonc.2022.888962. eCollection 2022.
- MacNaughton WK. Review article: new insights into the pathogenesis of radiation-induced intestinal dysfunction. Aliment Pharmacol Ther. 2000 May;14(5):523-8. doi: 10.1046/j.1365-2036.2000.00745.x.
- Lefevre JH, Amiot A, Joly F, Bretagnol F, Panis Y. Risk of recurrence after surgery for chronic radiation enteritis. Br J Surg. 2011 Dec;98(12):1792-7. doi: 10.1002/bjs.7655. Epub 2011 Sep 16.
- Hernandez-Moreno A, Vidal-Casariego A, Calleja-Fernandez A, Kyriakos G, Villar-Taibo R, Urioste-Fondo A, Cano-Rodriguez I, Ballesteros-Pomar MD. CHRONIC ENTERITIS IN PATIENTS UNDERGOING PELVIC RADIOTHERAPY: PREVALENCE, RISK FACTORS AND ASSOCIATED COMPLICATIONS. Nutr Hosp. 2015 Nov 1;32(5):2178-83. doi: 10.3305/nh.2015.32.5.9562.
- Anwar M, Ahmad S, Akhtar R, Mahmood A, Mahmood S. Antioxidant Supplementation: A Linchpin in Radiation-Induced Enteritis. Technol Cancer Res Treat. 2017 Dec;16(6):676-691. doi: 10.1177/1533034617707598. Epub 2017 May 22.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EC-075
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Radiation-induced Intestinal Injury
-
General Hospital of Shenyang Military RegionNot yet recruitingRadiation-Induced Intestinal InjuryChina
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNot yet recruitingRadiation-induced Intestinal Injury
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNot yet recruitingRadiation-induced Intestinal Injury
-
Fujian Cancer HospitalRecruitingRectal Diseases | Radiation InjuriesChina
-
Bispebjerg HospitalSygehus LillebaeltActive, not recruitingDNA Damage | Ultraviolet Rays; Injury | DNA Adduct Formation | DNA Damage, Radiation InducedDenmark
-
CSA Medical, Inc.WithdrawnRadiation Proctitis | Radiation Induced Proctitis
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNot yet recruitingChronic Radiation Injury
-
Affiliated Hospital to Academy of Military Medical...UnknownRadiation Injuries, ExperimentalChina
-
Sanford HealthCompletedRadiation Induced Fibrosis to the Head and NeckUnited States
-
Beijing Continent Pharmaceutical Co, Ltd.TerminatedRadiation-induced Lung InjuryChina
Clinical Trials on NCRT+TME
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNot yet recruitingRadiation-induced Intestinal Injury
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruitingRectal Neoplasm MalignantChina
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNot yet recruitingRadiation-induced Intestinal Injury
-
Fudan UniversityShanghai Zhongshan HospitalCompletedNeoplasm, Esophagus | Neoplasm, Squamous Cell
-
IRCCS San RaffaeleRecruiting
-
Sun Yat-sen UniversityPeking Union Medical College Hospital; RenJi Hospital; Shengjing Hospital; First... and other collaboratorsRecruitingSurgery | Rectal Neoplasms MalignantChina
-
Sun Yat-sen UniversityCompletedRectal Cancer | SurgeryChina
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Third Affiliated Hospital, Sun Yat-Sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern... and other collaboratorsRecruiting
-
Zhongnan HospitalNot yet recruiting